Gamida Cell Ltd. (GMDA)
Stock Price:
$5.62 USD
-0.04 (-0.71%)
Updated Oct 23, 2020 4:00 PM EDT - Market closed
Key Info
| Market Cap |
278.03M |
| Revenue (ttm) |
n/a |
| Net Income (ttm) |
-34.35M |
| Shares Out |
49.47M |
| EPS (ttm) |
-1.87 |
| PE Ratio |
n/a |
| Forward PE |
n/a |
| Dividend |
n/a |
| Dividend Yield |
n/a |
Stock Quote
| Trading Day |
Oct 23, 2020 |
| Last Price |
$5.62 |
| Previous Close |
$5.66 |
| Change ($) |
-0.04 |
| Change (%) |
-0.71% |
| Day's Open |
5.69 |
| Day's Range |
5.51 - 5.74 |
| Day's Volume |
122,512 |
| 52-Week Range |
2.60 - 7.70 |
More Stats
| Market Cap |
278.03M |
| Enterprise Value |
224.50M |
| Earnings Date (est) |
Nov 11, 2020 |
| Ex-Dividend Date |
n/a |
| Shares Outstanding |
49.47M |
| Float |
27.24M |
| EPS (basic) |
-1.17 |
| EPS (diluted) |
-1.87 |
| FCF / Share |
-1.64 |
| Dividend |
n/a |
| Dividend Yield |
n/a |
| Earnings Yield |
n/a |
| FCF Yield |
n/a |
| Payout Ratio |
n/a |
| Shares Short |
198,073 |
| Short Ratio |
1.44 |
| Short % of Float |
0.73% |
| Beta |
n/a |
| PE Ratio |
n/a |
| Forward PE |
n/a |
| P/FCF Ratio |
n/a |
| PS Ratio |
n/a |
| PB Ratio |
3.76 |
| Revenue |
n/a |
| Operating Income |
-48.25M |
| Net Income |
-34.35M |
| Free Cash Flow |
-40.99M |
| Net Cash |
53.53M |
| Net Cash / Share |
1.08 |
| Gross Margin |
n/a |
| Operating Margin |
n/a |
| Profit Margin |
n/a |
| FCF Margin |
n/a |
| ROA |
-38.63% |
| ROE |
-106.12% |
| ROIC |
-174.70% |
Stats based on trailing-twelve-month (ttm) numbers.
Analyst Summary
Analyst Ratings (6)
| Buy |
6 |
| Overweight |
0 |
| Hold |
0 |
| Underweight |
0 |
| Sell |
0 |
Price Target
$15.83*
(181.67% upside)
Low
13.0
Current: $5.62
High
20.0
Target: 15.83
*Average 12-month price target from 6 stock analysts.
Financial Performance
Financial numbers in millions USD.
Financial Overview
| Year | 2019 | 2018 | 2017 | 2016 |
|---|
| Revenue | - | - | - | - |
| Operating Income | -48.25 | -33.64 | -19.49 | -23.71 |
| Net Income | -34.35 | -52.93 | -19.01 | -22.67 |
| Shares Outstanding | 24.93 | 5.03 | 0.69 | 0.69 |
| Earnings Per Share | -1.69 | -10.53 | -27.56 | -32.86 |
| Operating Cash Flow | -37.93 | -26.43 | -16.55 | -12.59 |
| Capital Expenditures | -3.06 | -1.65 | -0.40 | -0.28 |
| Free Cash Flow | -40.99 | -28.07 | -16.95 | -12.87 |
| Cash & Equivalents | 55.40 | 60.69 | 41.08 | 18.06 |
| Total Debt | 1.87 | - | - | - |
| Net Cash / Debt | 53.53 | 60.69 | 41.08 | 18.06 |
| Assets | 68.78 | 65.16 | 44.92 | 19.18 |
| Liabilities | 33.79 | 40.48 | 21.97 | 8.22 |
| Book Value | 34.98 | 24.69 | 22.96 | 10.96 |
Numbers in millions USD, except per-share numbers.
Company Details
| Full Name |
Gamida Cell Ltd. |
| Country |
Israel |
| Employees |
79 |
| CEO |
Julian Adams |
Stock Information
| Ticker Symbol |
GMDA |
| Stock Exchange |
NASDAQ |
| Sector |
Healthcare |
| Industry |
Biotechnology |
| Unique Identifier |
NASDAQ: GMDA |
| IPO Date |
October 26, 2018 |
Description
Gamida Cell, a clinical stage biopharmaceutical company, develops cell therapies to cure blood cancers and serious blood diseases. The company's lead product candidate is omidubicel, a nicotinamide expanded hematopoietic stem cells and differentiated immune cells, including T cells that is in Phase III studies in patients with high-risk hematologic malignancies, as well as in Phase I/II clinical trial in patients with severe aplastic anemia. It is also developing GDA-201, a natural killer cell-based cancer immunotherapy, which is in Phase I/II studies for the treatment of relapsed or refractory non-Hodgkin lymphoma and multiple myeloma. The company was founded in 1998 and is headquartered in Jerusalem, Israel.